Stockreport

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024

Vir Biotechnology, Inc.  (VIR) 
PDF – Phase 2 SOLSTICE Safety and Efficacy Data in Hepatitis Delta Trial at Week 24 to Be Presented –– Oral and Five Poster Presentations Highlight Important Progress in Hep [Read more]